Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

World AIDS Day: Making progress

By Andrew Powaleny  |    December 1, 2015
Today is World AIDS Day and for many Americans who are HIV positive or who have AIDS, the outlook for those living with the disease has never – thankfully – been more promising. The HIV/AIDS...   Read More


By Andrew Powaleny  |    September 3, 2015
With Prescription Drug User Fee Act (PDUFA) VI FDA-Industry negotiations about to commence, we’re taking a look at what PDUFA is, how it works, and explaining why it has been a tremendous success...   Read More

Who is pushing for price controls? The answer may surprise you

By Priscilla VanderVeer  |    August 24, 2015
Progress in medical innovation over the past few years has been nothing short of remarkable. A once incurable disease – hepatitis C – now has cure rates above 90 percent. Patients previously...   Read More

Week in Review: The Latest from PhRMA

By Priscilla VanderVeer  |    June 26, 2015
Fighting High Cholesterol: The prevalence of high cholesterol among American adults underscores the importance of continued innovation. Take a look at the new infographic on fighting high...   Read More

Week in Review: The Latest from PhRMA

By Priscilla VanderVeer  |    May 29, 2015
Meet Tom: Check out our latest patient profile and see how out-of-pocket costs can limit access to needed medicines when it comes to managing HIV/AIDS. How Manufacturing Advances Medicine:...   Read More

Patient Profile: Out-of-Pocket Cost Burden for Patients Treating HIV/AIDS

By Allyson Funk  |    May 28, 2015
Check out our latest patient profile on the challenge of out-of-pocket costs when it comes to managing HIV/AIDS. Our past profiles have explored other chronic conditions like cancer, rheumatoid...   Read More

Why the World Looks to the U.S. for the Most Elusive Cures

By Robert Zirkelbach  |    February 3, 2015
Research and development (R&D) is the backbone of the biopharmaceutical industry and the reason why we have seen more than 450 new medicines approved in the U.S. since 2000 to help fight cancer,...   Read More

New Evidence of Discrimination in Essential Health Benefit Plans

By Tina Stow  |    January 30, 2015
While the Affordable Care Act (ACA) expanded access to health insurance coverage for millions, a new study from the Harvard T.H. Chan School of Public Health reveals that insurers may be...   Read More

Over $500 Billion Invested in R&D by PhRMA Member Companies Since 2000

By Robert Zirkelbach  |    January 22, 2015
Developing innovative, lifesaving medicines for patients is the sole focus of the biopharmaceutical industry. PhRMA member companies invested more than $50 billion in research and development (R&D)...   Read More

Working Together to Deliver Hope to Patients

By Robert Zirkelbach  |    January 20, 2015
When President Obama held his end-of-year press conference last month, he struck a clear and upbeat tone: “A new future is ready to be written. We've set the stage for this American moment.  And I'm...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates